Monte Rosa Turns A $50 Million Novartis Milestone Into Quarterly Profit
Collaboration revenue reached $54.4 million, but cash fell as drug-development spending increased.
Monte Rosa Therapeutics, which develops experimental medicines that enlist the body’s protein-disposal machinery, earned a $3.1 million profit in the third quarter, reversing a $27.1 million year-earlier loss, according to results announced Thursday with an SEC filing. Recognition of a $50 million Novartis milestone powered the revenue increase, while development spending rose and the payment remained uncollected at quarter-end.
Milestone Revenue, Cash Still Falling
Collaboration revenue of $54.4 million compared with $12.8 million a year earlier. The main contributor was Novartis’s September launch of a mid-stage Sjögren’s disease study of MRT-6160, which triggered the $50 million payment.
Novartis’s October launch of a psoriatic arthritis study triggered another $37.5 million milestone. That belongs outside the third quarter; together, the study starts triggered $87.5 million. Further trial launches could bring Monte Rosa more money from Novartis.
Quarterly profitability did not stop cash from declining. Cash, securities and restricted cash totaled $582.6 million on September 30, against $626.0 million on June 30—a $43.4 million decline primarily from operating expenditures. Neither milestone payment had arrived by September 30. Management expects its financial resources to cover operations into 2029.
Research and development expenses reached $45.4 million, versus $36.7 million a year earlier, primarily because of higher discovery and development spending. Administrative expenses were $10.9 million, against $9.1 million. Those totals included non-cash stock pay of $3.3 million and $3.0 million, respectively, compared with $2.5 million and $1.9 million.
The operating result remained a loss of $1.939 million, versus $32.975 million a year earlier. Interest income was $5.625 million. For the first nine months, Monte Rosa recorded an $84.837 million net loss, compared with $7.509 million of net income in the corresponding 2025 period.
Gout Leads The Next Trial Push
Monte Rosa’s three clinical programs span inflammatory and immune-mediated diseases and advanced prostate cancer. The Boston-based company develops drugs internally and through Novartis and Roche collaborations, with agreements providing upfront payments, milestones and royalties.
MRT-8102 anchors its next round of studies. In October, the company reported results from an early-stage trial involving 108 obese participants at elevated cardiovascular risk. Median removal of the targeted NEK7 protein was approximately 80% to 90% across the three doses tested, alongside reductions in inflammation-related markers. Side effects occurred about as often with treatment as with placebo, the company said.
Those findings informed dose selection for further testing. A mid-stage gout study is expected to begin in the fourth quarter of 2026, testing prevention of recurrent flares after acute flares have been managed. Initial results are expected in the second half of 2027.
Markus Warmuth, Monte Rosa’s chief executive officer, described the need in gout as “effective flare prevention that is well tolerated with prolonged use.”
Studies in stable coronary artery disease with residual inflammation and moderate to severe hidradenitis suppurativa are expected in the first half of 2027. The coronary study plans to combine plaque imaging with genetic and molecular measures to help shape a potential late-stage trial. Prioritizing these studies has moved the anticipated application to begin human testing of a next-generation NEK7 drug to 2027.
Prostate Cancer Results Come Next
Monte Rosa began dosing patients in August in a mid-stage MRT-2359 study combining the drug with apalutamide for previously treated metastatic, treatment-resistant prostate cancer with androgen receptor mutations. The study plans to enroll up to 25 patients, with Johnson & Johnson supplying clinical drug under an agreement.
Results from that study are expected in 2027. An update on six patients with androgen receptor mutations treated with MRT-2359 and enzalutamide in an earlier study is planned by year-end; interim findings were presented at the ASCO Genitourinary Cancers Symposium in February.
Beyond its clinical programs, Monte Rosa expects to seek permission to begin human studies of its CDK2- and cyclin E1-targeting cancer drugs in 2027.
The nearer-term milestones are the planned gout trial launch in the fourth quarter and the enzalutamide combination update by the end of 2026.
Sources
- 8-K Filing — Monte Rosa Therapeutics, Inc. (GLUE) — SEC EDGAR
- Exhibit glue-ex99_1.htm — Monte Rosa Therapeutics, Inc. 8-K exhibit — SEC EDGAR
- Monte Rosa Therapeutics Announces Third Quarter 2026 — globenewswire.com